Ligand Pharmaceuticals LGND Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $153.56M+216% | $124.45M+3,187% | $48.58M+7.4% | -$75.86M-280% | -$132.62M-238% | ||
| $33.22M-5.7% | $33.78M-4.2% | $34.19M-3.8% | $34.91M-0.7% | $35.24M-1.5% | ||
| $49.61M+19.3% | $46.85M+14.0% | $40.1M+2.1% | $40.53M+30.7% | $41.59M+53.2% | ||
| $123.5M+134% | $49.36M-49.1% | $31.92M-58.4% | $55.36M+15.9% | $52.87M+53.5% | ||
| $466K-75.9% | $452K-75.2% | $1.16M-24.3% | $1.74M+22.5% | $1.93M+59.2% | ||
| -$476.56M-253% | -$377.32M-163% | -$397.84M-245% | -$90.9M-2.9% | -$135M-419% | ||
| $418.84M+422% | $428.22M+341% | $440.28M— | $85.72M— | $80.21M— | ||
| $67.11M+3,289% | $102.62M+108% | $75.76M— | $49.53M— | -$2.1M— | ||
| $123.03M+142% | $48.91M-48.6% | $30.76M-59.0% | $53.62M+15.7% | $50.94M+52.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.